Table 2.
HIV-1 and HBV Activity of Bis-disulfide Conjugates 13a–ea
| HIV-1 | HBV | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| compd | EC50b (PBMCs) | CC50c (PBMCs) | TI (CC50/EC50) | EC50b (HepG2) | CC50c (HepG2) | TI (CC50/EC50) |
| TDF | 0.0046 | 43.7 | 9500 | 0.34 | 29.2 | 86 |
| 13a | 0.349 | >100.0 | >287 | >100 | >100.0 | >1 |
| 13b | 1.18 | >100.0 | >85.0 | >100 | >100.0 | >1 |
| 13c | 0.189 | >100.0 | >529 | >100 | >100.0 | >1 |
| 13d | 6.32 | >25 | 4.0 | >25 | >25 | >1 |
| 13e | 0.331 | >25 | >76 | >25 | >25 | >1 |
a
All data represent an average of triplicate experiments.
b
EC50, effective concentration (in μM) required to inhibit HIV-1 or HBV by 50%.
c
CC50, effective concentration (in μM) required to reduce the viability of uninfected cells by 50%.